Cell Biotech Co. Ltd (049960) — Cash Flow-to-Debt Ratio
Cell Biotech Co. Ltd (049960) has a Cash Flow-to-Debt Ratio of 0.56x as of September 2025, meaning its operating cash flow of ₩4.15 Billion could theoretically repay 1% of its total liabilities (₩7.46 Billion) in one year. See financial agility of Cell Biotech Co. Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cell Biotech Co. Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Cell Biotech Co. Ltd across 14 annual periods. For the full cash flow conversion analysis, see 049960 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Cell Biotech Co. Ltd (2011–2024)
Year-by-year debt coverage analysis for Cell Biotech Co. Ltd. Check 049960 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 3.09x | ₩19.27 Billion | ₩6.23 Billion | ▲ +127.8% |
| 2023 | 1.36x | ₩7.82 Billion | ₩5.76 Billion | ▼ -17.9% |
| 2022 | 1.65x | ₩12.81 Billion | ₩7.75 Billion | ▼ -31.3% |
| 2021 | 2.41x | ₩14.89 Billion | ₩6.19 Billion | ▲ +33.8% |
| 2020 | 1.80x | ₩9.56 Billion | ₩5.32 Billion | ▼ -17.3% |
| 2019 | 2.18x | ₩10.23 Billion | ₩4.70 Billion | ▲ +0.0% |
| 2018 | 2.18x | ₩13.98 Billion | ₩6.42 Billion | ▼ -39.3% |
| 2017 | 3.59x | ₩22.53 Billion | ₩6.28 Billion | ▲ +27.1% |
| 2016 | 2.82x | ₩17.99 Billion | ₩6.38 Billion | ▼ -3.9% |
| 2015 | 2.94x | ₩18.24 Billion | ₩6.21 Billion | ▲ +55.4% |
| 2014 | 1.89x | ₩9.91 Billion | ₩5.24 Billion | ▼ -23.3% |
| 2013 | 2.46x | ₩8.99 Billion | ₩3.65 Billion | ▲ +55.1% |
| 2012 | 1.59x | ₩6.17 Billion | ₩3.88 Billion | ▲ +45.1% |
| 2011 | 1.10x | ₩5.45 Billion | ₩4.98 Billion | — |